Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multicenter study with recombinant human erythropoietin

H Tanaka1, E Kan, Y Takegaki

  • 1Department of Urology, Ohno Memorial Hospital, Osaka, Japan.

Artificial Organs
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.

bioRxiv : the preprint server for biology·2025
Same author

Comparison of central corneal thickness measurements using three different imaging devices.

Journal francais d'ophtalmologie·2023
Same author

Prenatal diagnosis of familial atretic encephalocele.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2018
Same author

Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism.

Journal of endocrinological investigation·2013
Same author

Transport of living cells with magnetically assembled nanowires.

Biomedical microdevices·2006
Same author

Scale-up and cost evaluation of a foamed emulsion bioreactor.

Environmental technology·2006

This study found that a low initial dose of recombinant human erythropoietin (rh-EPO) effectively treated anemia in hemodialysis patients, showing excellent efficacy and safety. Reticulocyte counts reliably predicted rh-EPO therapy response.

Area of Science:

  • Nephrology
  • Hematology

Background:

  • Anemia is a common complication in patients undergoing hemodialysis.
  • Recombinant human erythropoietin (rh-EPO) is a standard treatment for anemia in this population.
  • Optimizing rh-EPO dosing and monitoring efficacy are crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of rh-EPO (Epoetin beta) in treating anemia among hemodialysis patients.
  • To compare the study's outcomes with other multicenter rh-EPO studies.
  • To identify reliable indicators for assessing rh-EPO therapy effectiveness.

Main Methods:

  • A multicenter study involving 172 hemodialysis patients (77 males, 95 females; mean age 53.9 years).
  • Intravenous administration of rh-EPO (Epoetin beta) starting at 1,500 U, with potential increase to 3,000 U based on efficacy.

Related Experiment Videos

  • Dose adjustments were made to maintain a target hematocrit of 30%.

    • Main Results:

    • The study demonstrated excellent efficacy, safety, and favorable laboratory data changes compared to other multicenter studies.
    • A lower incidence of hypertension was observed, attributed to the low initial rh-EPO dose.
    • Reticulocyte counts proved to be an earlier and more reliable indicator of rh-EPO therapy efficacy than hematocrit or hemoglobin levels.

    Conclusions:

    • A low initial dose of rh-EPO is effective and safe for managing anemia in hemodialysis patients.
    • Reticulocyte count is a superior biomarker for monitoring rh-EPO treatment response.
    • Iron supplementation should be promptly initiated and monitored alongside serum iron and ferritin levels.